Whether Medicaid pays for a GLP-1 medication comes down to two questions: why it is being prescribed and which state you live in. Almost every state Medicaid program covers GLP-1s for type 2 diabetes — Ozempic, Mounjaro, and Rybelsus — because that is a federally required benefit. Coverage for obesity or weight loss — Wegovy and Zepbound — is optional for states, and far fewer offer it. As of January 2026, only about 13 state Medicaid programs cover GLP-1s for weight loss under fee-for-service, down from 16 in late 2025, according to KFF, which maintains the authoritative, regularly updated tracker.[1] Because that number keeps moving, this page won’t freeze a precise per-state grid that goes stale within weeks. Instead, we’ll show you how to confirm your own coverage today — the one skill that stays useful no matter which way your state votes next.
The one distinction that decides everything: diabetes vs. obesity
The same molecules are sold under different brand names for different uses. Semaglutide is Ozempic and Rybelsus when approved for type 2 diabetes, and Wegovy when approved for chronic weight management. Tirzepatide is Mounjaro for diabetes and Zepbound for weight loss. That labeling difference is the hinge Medicaid coverage turns on. (For a plain-language primer on how these drugs work, see our guide to how GLP-1 medications work and the drug page for semaglutide.)
Under federal Medicaid rules, states must cover a participating manufacturer’s drug for its FDA-approved indications — and type 2 diabetes qualifies. Drugs used only for weight loss, however, sit on a short list of categories that federal law lets states exclude. So a diabetes GLP-1 is effectively mandatory coverage, while an obesity GLP-1 is a state choice.[1] The practical upshot: if you have type 2 diabetes, a GLP-1 is usually covered (after prior authorization). If you are seeking one purely to lose weight, coverage depends entirely on where you live.
How many states cover GLP-1s for weight loss right now?
As of January 2026, KFF counts 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service — roughly 10 with full coverage and 3 with restricted coverage.[1] That is down from 16 states in KFF’s October 2025 survey. Four states — California, New Hampshire, Pennsylvania, and South Carolina — dropped obesity coverage effective January 1, 2026, citing state budget pressure and the drugs’ cost.[1] North Carolina cut its weight-loss coverage on October 1, 2025 during a legislative budget standoff, then reinstated it on December 12, 2025 under the governor’s directive — which is what kept the national total at 13 rather than 12.[3]
This is exactly why we don’t publish a fake 50-state grid. State budgets shift, off-cycle changes land mid-year, and a table that looks authoritative can be wrong within a month. For the current full state list, KFF’s tracker is the source we trust and check against — and it’s where we’d send you before you make a decision.[1]
| Your question | Honest answer | What to do next |
|---|---|---|
| Does Medicaid cover a GLP-1 for type 2 diabetes? | Almost always yes (Ozempic, Mounjaro, Rybelsus), usually with prior authorization. | Confirm the specific product is on your state’s preferred drug list. |
| Does Medicaid cover Wegovy or Zepbound for weight loss? | Only in about 13 states as of Jan 2026, and often with strict criteria. | Check KFF’s tracker, then your state’s drug list and your plan. |
| My state dropped coverage this year — is that final? | Not necessarily; coverage has been cut and later restored (e.g., North Carolina). | Ask about medical exceptions and watch for policy updates. |
| Is coverage the same in every state? | No. Obesity coverage is optional, so it varies widely and changes often. | Verify for your state today — don’t rely on last year’s list. |
| Will federal rules expand coverage soon? | Possibly. The voluntary BALANCE model may add options from about May 2026. | Treat it as emerging, not guaranteed; keep checking. |
Why diabetes coverage is broad but obesity coverage isn’t
The gap is written into federal law, not left to guesswork. Since March 2024, states have been required to cover GLP-1s approved for cardiovascular risk reduction, and since December 2024, those approved for obstructive sleep apnea.[1][5] These federally required uses matter for real people: someone who qualifies on a medical ground — diabetes, heart disease, or sleep apnea — may get a GLP-1 covered even in a state that does not cover it for weight loss alone. If any of those conditions apply to you, that is the door most likely to open.
The hoops you’ll meet where coverage does exist
Even in a covering state, a weight-loss GLP-1 is rarely a simple yes. Expect one or more utilization controls before approval:
- Prior authorization — your prescriber must submit paperwork justifying the drug before Medicaid will pay.[1] See our walkthrough of prior authorization for GLP-1s.
- BMI thresholds — commonly a body mass index of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or prediabetes. Some states set a higher bar (for example, BMI 40 or above).
- Documented lifestyle attempts — evidence you have tried diet and physical activity, sometimes for a defined number of months.
- Step therapy — being required to try a lower-cost medication first before a GLP-1 is approved.
Because criteria and covered brands differ by state, the numbers above are typical patterns, not a promise about your plan. Confirm the exact rule with your program.
How to find out what your state Medicaid covers
This is the durable part of this page — the process barely changes even as the state list does. Four steps, in order:
- Find your state’s preferred drug list (formulary). Search “[your state] Medicaid preferred drug list,” or start from Medicaid.gov’s state prescription drug resources.[6] Look for Wegovy, Zepbound, Ozempic, Mounjaro, or Rybelsus, and note any coverage criteria listed beside them.
- Call the number on your Medicaid card. Ask specifically: “Is [drug name] covered for [diabetes / weight loss], and what are the prior-authorization criteria?” Get the answer in writing if you can.
- Ask your prescriber’s office to run a benefits check. Many clinics can verify coverage and start the prior-authorization request in the same visit.
- Estimate your cost if it isn’t covered. Compare our Wegovy cost and Zepbound cost guides, review the full picture in our GLP-1 insurance coverage explainer, or try the cost & coverage estimator.
What about Medicare?
Medicare plays by different rules, and it’s worth knowing the difference if you or a family member are on it. By law, Medicare Part D is prohibited from covering drugs used only for weight loss, so Wegovy and Zepbound are not covered for obesity on its own.[7] Medicare does cover GLP-1s for approved medical uses: type 2 diabetes; Wegovy for cardiovascular risk reduction (FDA-approved in 2024); and Zepbound for moderate-to-severe obstructive sleep apnea (FDA-approved in December 2024).[5] The pattern is the same as Medicaid: a qualifying medical indication is what unlocks coverage.
A change to watch: the federal BALANCE model
In December 2025, CMS announced a voluntary program called the BALANCE model, under which CMS would negotiate GLP-1 pricing and coverage terms on behalf of participating state Medicaid agencies and Medicare Part D plans.[4] State Medicaid programs can begin joining on a rolling basis starting around May 2026.[2] Because participation is voluntary for states and drug manufacturers alike, it may broaden access in some places — but it is an emerging development, not a guarantee that your state will opt in or that a specific drug will be covered. Don’t put off checking your current options in the hope that it changes things for you.
If you’re denied — and when to talk to a clinician
A denial is not the end of the road. You have the right to appeal, and prior-authorization denials are frequently overturned when the prescriber documents medical necessity. Start with our guide to appealing a GLP-1 insurance denial, and make sure your prior-authorization paperwork is complete before it goes in.
When to loop in a clinician: if you have type 2 diabetes, heart disease, or sleep apnea, say so — a medically covered indication can unlock coverage that weight-loss criteria alone won’t. Never start or stop a prescription based on a coverage article; those decisions belong with your clinician, who can weigh your health history, and with your Medicaid plan, which sets the final rules.
Bottom line: this page is information to help you verify coverage — not medical or insurance advice. Every figure here is current as of January 2026 and changes often, so confirm today with KFF’s live tracker, your state’s Medicaid drug list, and the number on your card. If you want to compare drugs and prices while you check, start with the weight & metabolism hub.
